Experience with nutraceutical supplements in the treatment of pelvic pain in gynaecology: case reports

F. Alfonso, Francisco Nohales Alfonso
Drugs in context · 2022 · vol. 11 , pp. 1–7 · doi:10.7573/dic.2021-10-8 · PMID:35106067 · W4206305452
article OA: gold CC0
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

Three women with gynecological pelvic pain experienced significant pain resolution with a multimodal approach including behavioral adjustments, physical interventions, and the nutraceutical supplement alpha-lipoic acid, palmitoylethanolamide, and myrrh.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 ⓘ

This case report series described three women presenting with acute episodes of gynecological pelvic pain, including one with biopsy-confirmed peritoneal endometriosis, managed in routine clinical practice using early assessment and a multimodal strategy. Across cases, investigations (including objective pain/source evaluation) were followed by a combined approach of behavioral and physical interventions plus a nutraceutical supplement containing alpha-lipoic acid, palmitoylethanolamide, and myrrh, with other pharmacologic modalities (e.g., hormones, antineuropathic agents, and in some cases corticosteroid or botulinum toxin infiltrations) added based on individual histories. The authors report that pelvic pain and associated dyspareunia (Marinoff scale 2–3) were largely resolved in each case, with subsequent reduction or withdrawal of other medications. A key limitation is that these are non-protocolized case studies without a controlled design, so causality cannot be established. This paper is centrally about endometriosis — it includes a biopsy-confirmed endometriosis case in which multimodal pelvic pain management incorporated the ALA+PEA+myrrh nutraceutical supplement.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Three women with diverse gynaecological medical histories (one with endometriosis, one having had an episiotomy and obstetric anal sphincter injury during a recent delivery, and one having had a recent cystectomy of the left Bartholin gland) developed acute episodes of gynaecological pelvic pain. In each case, clinical investigations (including objective tools for assessing the source, nature and severity of the pain) were conducted early on, and a multimodal approach to therapy was introduced to control the pain and avoid central sensitization or chronicity. The multimodal approach included hormone therapy, antineuropathic medications, and corticosteroid or botulinum neurotoxin infiltrations in some of the patients according to their medical conditions but consistently included behavioural adjustments, physical interventions and a nutraceutical supplement (alpha-lipoic acid, palmitoylethanolamide and myrrh). In each case, the pelvic pain and associated dyspareunia (Marinoff scale 2 or 3) were largely resolved. These clinical cases support the results of clinical trials showing the benefits of alpha-lipoic acid + palmitoylethanolamide + myrrh for the management of gynaecological pelvic pain, enabling the reduction or withdrawal of other analgesic, anti-inflammatory and antineuropathic medications.

My notes (saved in your browser only)

Condition tags

endometriosisdyspareunia

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (36)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:23:57.700195+00:00
License: CC0 · commercial use OK